LifeStance Health vs U S Physical Therapy
LFST and USPH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFST and USPH compare
LifeStance Health is the larger company, worth 3.7 times as much as U S Physical Therapy ($5.5B against $1.5B).
LifeStance Health grew revenue faster over the last twelve months (22.6% versus 10.4% for U S Physical Therapy).
LifeStance Health keeps more of each dollar of sales as profit, with a net margin of 4.3% compared with 3.6% at U S Physical Therapy.
U S Physical Therapy pays a dividend yielding 1.8%; LifeStance Health does not pay one.
LifeStance Health scores higher on the StockData Score (12 against 9 for U S Physical Therapy), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFST | USPH |
|---|---|---|
| Size and price | ||
| Market cap | $5.5B | $1.5B |
| Share price | $14.37 | $100.10 |
| Change, 1 year | 123% | 36.6% |
| Change, 5 years | 66.1% | 9.9% |
| Beta (5Y) | 1.18 | 0.72 |
| Employees | 11K | 7,294 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 1 (better) |
| Valuation | ||
| P/E | 75.6× | – |
| P/S | 3.3× | 1.8× (better) |
| P/B | 3.7× | 3.5× (better) |
| EV/EBITDA | 37.4× | 17.3× (better) |
| P/FCF | 30.6× | 21.6× (better) |
| FCF yield | 3.3% | 4.6% (better) |
| Fair value | $5.90 | $82.03 |
| Margin of safety | −143% | −22.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 22.6% (better) | 10.4% |
| Revenue growth, 5Y average | – | 13.0% |
| Net income growth (TTM) | – | −32.5% |
| EPS growth, 5Y average | – | −10.6% |
| Profitability | ||
| Gross margin | – | 18.8% |
| Operating margin | 6.2% | 9.1% (better) |
| Net margin | 4.3% (better) | 3.6% |
| FCF margin | 10.7% (better) | 8.2% |
| Return on equity | 4.8% | 6.5% (better) |
| Return on invested capital | 5.4% | 9.1% (better) |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.57 |
| Net debt / EBITDA | 0.35 (better) | 2.11 |
| Interest coverage | 10.6× | – |
| Current ratio | 1.44 (better) | 1.42 |
| Altman Z-score | 5.26 (better) | 2.85 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.8% |
| Years of dividend growth | – | 5 |
| Dividend growth, 5Y average | – | 41.3% |
| Shareholder yield | 0.00% | 1.8% (better) |
| Ownership | ||
| Held by institutions | 98.7% | 109% |
| Held by insiders | 64.7% | 2.6% |
| Insider net buying, 12 months | −$847M | −$397K (better) |
| Short interest, % of float | 10.1% | 7.8% |
Go deeper
- LFST stock overview
- LFST income statement
- LFST valuation and score
- USPH stock overview
- USPH income statement
- USPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.